Oppenheimer upgraded BridgeBio (BBIO) to Outperform from Perform with a $60 price target The firm expects the outperformance of BridgeBio shares to continue as 2025 Attruby sales beat consensus estimates. The commercial success of Attruby will be compounded by positive clinical results from autosomal dominant hypocalcemia type 1 and limb-girdle muscular dystrophy type 2i clinical trials towards the end of the year, the analyst tells investors in a research note. Oppenheimer cites confidence in BridgeBio’s execution and clinical catalysts late in 2025 for the upgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio upgraded to Outperform from Perform at Oppenheimer
- BridgeBio Pharma Enters Royalty Purchase Agreement
- Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma’s Path to Profitability
- BridgeBio raises $300M via parital capped monetization of European royalty
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts